Expertise Matters: Building Your Rare Ovarian Cancer Care Team
At a Glance
For rare ovarian cancer, assembling a specialized multidisciplinary care team at a high-volume cancer center is crucial. This team should include a gynecologic oncologist and a subspecialized pathologist to ensure an accurate diagnosis and access to cutting-edge clinical trials.
When you have a rare ovarian cancer, your most important “treatment” isn’t a drug—it’s the team of experts you assemble. Because rare subtypes behave so differently from common ovarian cancer, being treated at a high-volume, specialized center (often a National Cancer Institute (NCI)-designated center) is associated with significantly better outcomes and more accurate diagnoses [1][2][3].
The Multidisciplinary Team (MDT)
Rare cancers require a “brain trust” of specialists who look at your case from every angle. A true multidisciplinary team for rare ovarian cancer should include:
- Gynecologic Oncologist: A surgeon and cancer specialist who coordinates your overall care. They are specifically trained to perform the precise surgeries required for ovarian cancers [4].
- Subspecialized Pathologist: This is critical. A general pathologist may see your rare tumor once a year, but a specialist sees them daily, reducing the high risk of misdiagnosis in rare subtypes [5][6].
- Medical Oncologist: Especially one with expertise in targeted therapies (like MEK inhibitors) or hormonal treatments, rather than just standard chemotherapy [4][7].
- Genetic Counselor: Essential for identifying rare hereditary links that could affect your treatment and your family’s health. For example, DICER1 mutations are linked to certain sex cord-stromal tumors [8][9], and Lynch Syndrome is frequently linked to endometriosis-associated tumors like Clear Cell carcinoma [10][11].
Why Specialized Centers Matter
In rare disease, “volume” equals “expertise.” High-volume centers are more likely to follow the latest evidence-based guidelines, such as utilizing fertility-sparing surgery for young patients with germ cell or sex cord tumors [12][3]. They also have access to Molecular Tumor Boards, where experts review your tumor’s DNA to find “actionable” targets that standard tests might miss [13][14].
Accessing Rare Disease Clinical Trials
For many rare ovarian cancers, the best treatment option is often a clinical trial, as standard-of-care options for recurrent disease can be limited [15][16]. Modern “precision medicine” trials are designed specifically for rare diseases:
- Basket and Umbrella Trials: These innovative designs (like the BOUQUET or RAMP studies) group patients by their tumor’s genetic mutations rather than just where the cancer started [13][17].
- Histology-Specific Trials: Some trials focus solely on one rare type, such as the RAMP 301 study (NCT06072781) for recurrent Low-Grade Serous Ovarian Cancer (LGSOC) or the HI-MOC study (NCT05123807) for Mucinous Ovarian Cancer [18][19].
- Where to Look: Use specific terms like “Clear Cell Ovarian” or “Sex Cord-Stromal” when searching databases like ClinicalTrials.gov, rather than just “Ovarian Cancer,” which will mostly return results for the common high-grade type [18][19].
Building your team at a center that actively participates in these trials ensures you aren’t just getting the “standard” treatment, but the one that is most likely to work for your unique biology [20][21]. As you progress through treatment, this team will also guide you through your Long-Term Survivorship and Follow-Up.
Common questions in this guide
Why do I need a subspecialized pathologist for rare ovarian cancer?
What doctors should be on my ovarian cancer care team?
Should I travel to a specialized center for my rare ovarian cancer treatment?
What is a molecular tumor board?
How do I find clinical trials for rare ovarian cancer?
Get notified when new evidence is published on Rare ovarian cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.
Dantkale KS, Agrawal M
Cureus 2024; (16(1)):e52650 doi:10.7759/cureus.52650.
PMID: 38380211 - 2
Mixed ovarian germ cell tumor in a child: A case report of a rare association.
Benradi L, El Haissoufi K, Ammor A, et al.
Annals of medicine and surgery (2012) 2021; (65()):102237 doi:10.1016/j.amsu.2021.102237.
PMID: 33898029 - 3
ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.
Sessa C, Schneider DT, Planchamp F, et al.
The Lancet. Oncology 2020; (21(7)):e360-e368 doi:10.1016/S1470-2045(20)30091-7.
PMID: 32615119 - 4
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
Falzone L, Scandurra G, Lombardo V, et al.
International journal of oncology 2021; (59(1)).
PMID: 34132354 - 5
Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review.
Gao L, Huang T, Zhong L, et al.
Reproductive sciences (Thousand Oaks, Calif.) 2024; (31(6)):1626-1631 doi:10.1007/s43032-023-01443-1.
PMID: 38216775 - 6
Rare ovarian tumors: an update on diagnosis and treatment.
Debuquoy C, Romeo C, Vanacker H, Ray-Coquard I
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):879-887 doi:10.1136/ijgc-2020-001235.
PMID: 32461259 - 7
Low-grade Serous Tumors: Are We Making Progress?
Pauly N, Ehmann S, Ricciardi E, et al.
Current oncology reports 2020; (22(1)):8 doi:10.1007/s11912-020-0872-5.
PMID: 31989304 - 8
Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.
Pokharel HP, Hacker NF, Andrews L
The Australian & New Zealand journal of obstetrics & gynaecology 2016; (56(6)):633-638 doi:10.1111/ajo.12504.
PMID: 27530527 - 9
Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature.
Mercier AM, Zorn KK, Quick CM, Huffman LB
Gynecologic oncology reports 2021; (37()):100806 doi:10.1016/j.gore.2021.100806.
PMID: 34169133 - 10
Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.
Phuong DJ, Pirtz MG, Ralston CQ, et al.
Cancers 2025; (17(4)) doi:10.3390/cancers17040604.
PMID: 40002199 - 11
The unique metabolome of clear cell ovarian carcinoma.
Ji JX, Hoang LN, Cochrane DR, et al.
The Journal of pathology 2024; (264(2)):160-173 doi:10.1002/path.6329.
PMID: 39096103 - 12
Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.
Vasta FM, Dellino M, Bergamini A, et al.
Biomedicines 2020; (8(12)) doi:10.3390/biomedicines8120554.
PMID: 33265938 - 13
[Treatments for rare ovarian tumors: What's new?]
Lebreton C, Quesada S, Bini M, et al.
Bulletin du cancer 2023; (110(7-8)):818-824 doi:10.1016/j.bulcan.2023.03.007.
PMID: 37045734 - 14
Update on new treatments for rare ovarian tumours.
Quesada S, Bini M, Lebreton C, Ray-Coquard I
Current opinion in obstetrics & gynecology 2023; (35(1)):27-33 doi:10.1097/GCO.0000000000000836.
PMID: 36440753 - 15
Primary mucinous ovarian cancer: options for surgery and chemotherapy.
Kurnit KC, Frumovitz M
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(11)):1455-1462 doi:10.1136/ijgc-2022-003806.
PMID: 36229081 - 16
Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study.
Chou CY, Cheng WF, Chen MY, et al.
Cancers 2022; (14(7)) doi:10.3390/cancers14071746.
PMID: 35406519 - 17
The highs and lows of serous ovarian cancer.
Grisham RN, Manning-Geist BL, Chui MH
Cancer 2023; (129(17)):2613-2620 doi:10.1002/cncr.34903.
PMID: 37366225 - 18
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.
Blanc-Durand F, Ngoi N, Lim D, et al.
Cancer treatment reviews 2025; (138()):102977 doi:10.1016/j.ctrv.2025.102977.
PMID: 40517636 - 19
Targeting RAS-RAF-MEK-ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework.
Bartl T, Cacsire Castillo-Tong D
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(4)):104485 doi:10.1016/j.ijgc.2026.104485.
PMID: 41680018 - 20
Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.
Champer M, Miller D, Kuo DY
Gynecologic oncology reports 2019; (28()):26-28 doi:10.1016/j.gore.2019.01.007.
PMID: 30809568 - 21
Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report.
Silva R, Moran B, Das S, et al.
Case reports in women's health 2022; (34()):e00395 doi:10.1016/j.crwh.2022.e00395.
PMID: 35198414
This page provides educational information about assembling a care team for rare ovarian cancer. Always consult a gynecologic oncologist or specialized cancer center for personalized medical advice regarding your specific diagnosis and treatment.